5,572 reports of this reaction
5.5% of all RIOCIGUAT reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for RIOCIGUAT, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 5,572 FDA adverse event reports linking RIOCIGUAT to DYSPNOEA. This represents approximately 5.5% of all 100,865 adverse event reports for this drug.
RIOCIGUAT has an overall safety score of 85 out of 100. Patients taking RIOCIGUAT who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among RIOCIGUAT users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for RIOCIGUAT:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 5,572 FDA reports for RIOCIGUAT. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 5.5% of all adverse event reports for RIOCIGUAT, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking RIOCIGUAT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.